arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Nuvation Bio Inc.

NUVB

$6.60 ▲ +0.49 (+8.02%) at close

7 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Nuvation Bio Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3M

Dividend Yield —

Revenue Growth 699.0%

Op. Margin -338.7%

ROIC -60.4% ↗

FCF / Share $-507.78 ↘

Trailing P/E —

Price / Book 7.3x

FCF Yield —

Debt / Equity 0.17

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$62.90M

↑ +699.0% —

Net Income Profit after all expenses

$-204.63M

↑ +64.0% —

FCF / Share Free cash flow per share

$-507.78

↓ -4.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Revenue Growth YoY (%)	699.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+8637%)	—	—	—	—	—	—
EPS Growth YoY (%)	71.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-502.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	27.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-9.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	64.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-649.2% Weak ↓ Weak Declining Year-over-year change in net income	27.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-20.0% Weak Weak Year-over-year change in net income	-108.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-4.6% Weak ↑ Weak Improving Year-over-year change in free cash flow	-56.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	29.9% Excellent Excellent Year-over-year change in free cash flow	-28.7% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Operating Margin (%) (%)	-338.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2358%)	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-325.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2811%)	—	—	—	—	—	—
FCF Margin (%) (%)	-275.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Return on Invested Capital (%)	-60.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-127.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.5% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-18.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-20.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-35.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-109.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-17.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-19.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-66.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-546%)	-122.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-916%)	-12.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-184%)	-15.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-206%)	-11.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-178%)	-19.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-229%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Debt to Equity (x)	0.17x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-71%)	0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-98%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—
Interest Coverage (x)	-73.93x Weak Weak Operating income divided by interest expense Optimal: > 5x	-1737.91x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-111.15M	$-29.44M	$-42.65M	$-101.10M	$-132.42M	$-29.75M	$0.00
Debt / EBITDA (x)	-0.25x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Revenue per Share (USD)	$184.17	$29.29	$0.00	—	—	—	—
Basic EPS, GAAP (USD)	$-0.60	$-2.11	$-0.35	$-0.48	$-0.44	—	—
Free Cash Flow per Share (USD)	$-507.78	$-485.22	$-310.67	$-443.46	$-344.59	—	—
Book Value per Share (USD)	$0.90	$1.37	$2.76	$3.00	$3.42	$1.44	—
Tangible Book Value per Share (USD)	$0.90	$1.37	$2.76	$3.00	$3.42	$1.44	—
Basic Weighted Avg Shares (shares)	341,541	268,772	218,880	216,721	197,887	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Working Capital (USD)	$489.29M	$468.01M	$602.46M	$654.16M	$755.15M	$214.13M	—
LT Debt (USD)	$47.21M	—	—	—	—	—	—
Total Equity (USD)	$305.72M	$463.79M	$605.12M	$655.08M	$746.00M	$215.08M	$0.00

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Apr 23, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$62.90M	$7.87M	$0.00	—	—	—	—
Net Income, GAAP (USD)	$-204.63M	$-567.94M	$-75.80M	$-104.20M	$-86.85M	$-41.66M	—
Operating Cash Flow (USD)	$-173.43M	$-130.41M	$-68.00M	$-96.11M	$-68.19M	$-36.53M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Nuvation Bio Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NUVB with peers